Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Early anthracycline cardiotoxicity

M R Bristow, P D Thompson, R P Martin

    The American Journal of Medicine
    |November 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Quasiparticle Poisoning of Superconducting Qubits from Resonant Absorption of Pair-Breaking Photons.

    Physical review letters·2024
    Same author

    The ratios of iron to oxygen, iron to colour and oxygen to colour in the blood of men and women.

    The Journal of physiology·2010
    Same author

    Fiber optics oximeter-densitometer for cardiovascular studies.

    Applied optics·2010
    Same author

    Specific cardiac indications for routine lidocaine use.

    Anesthesia progress·2009
    Same author

    The distribution of the orphan bombesin receptor subtype-3 in the rat CNS.

    Neuroscience·2003
    Same author

    Increased cortical expression of the orexin-1 receptor following permanent middle cerebral artery occlusion in the rat.

    Neuroscience letters·2002
    Same journal

    Mineralocorticoid Antagonists for Post-MI HFpEF: Plausible Biology Meets Low Residual Risk?

    The American journal of medicine·2026
    Same journal

    GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

    The American journal of medicine·2026
    Same journal

    Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

    The American journal of medicine·2026
    Same journal

    Cave Canem - Beware of the Dog.

    The American journal of medicine·2026
    Same journal

    Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

    The American journal of medicine·2026
    Same journal

    Mesenteric panniculitis.

    The American journal of medicine·2026
    See all related articles

    Anthracycline antibiotics like daunorubicin and doxorubicin can cause significant heart damage early in treatment. This cardiotoxicity may occur at lower doses than previously thought, impacting patients with existing heart conditions.

    Area of Science:

    • Cardiology
    • Oncology
    • Pharmacology

    Background:

    • Anthracycline antibiotics (daunorubicin, doxorubicin) are widely used chemotherapy agents.
    • Cardiotoxicity is a known, dose-dependent side effect of these drugs, typically associated with chronic cardiomyopathy.

    Observation:

    • This study describes eight patients who developed cardiac dysfunction within four weeks of anthracycline treatment.
    • Four patients presented with pericarditis and myocardial dysfunction; histopathology revealed acute myocyte damage.
    • Four patients presented with heart failure, particularly elderly patients or those with pre-existing cardiac disease.

    Findings:

    • Clinically significant cardiotoxicity, including pericarditis, myocardial dysfunction, and heart failure, can manifest acutely after anthracycline administration.

    Related Experiment Videos

  • One patient experienced myocardial infarction shortly after a daunorubicin dose, with prior evidence of ischemia.
  • These events occurred at cumulative doses considerably lower than those typically linked to chronic cardiomyopathy.

    • Implications:

    • Anthracycline-induced cardiotoxicity may present earlier and at lower cumulative doses than previously recognized.
    • This highlights the need for vigilant cardiac monitoring in patients receiving anthracyclines, especially those with risk factors.
    • Early detection and intervention are crucial to mitigate severe cardiac events in cancer patients undergoing chemotherapy.